Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia

Fox, Lindy P.; Geyer, A; Husain, Sameera; Grossman, Marc E.

doi:10.1080/10428190500254299

Cited by 39 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In IBD, classic and pustular PGs are the subtypes most frequent; whereas in myeloproliferative diseases, bullous PG is the most common variant. 69,70 Vegetans PG is usually not associated with any systemic diseases.…”

Section: Pyoderma Gangrenosummentioning

confidence: 99%

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

113

View full text Add to dashboard Cite

The skin is one of the most common extraintestinal organ system affected in patients with inflammatory bowel disease (IBD), including both Crohn's disease and ulcerative colitis. The skin manifestations associated with IBD are polymorphic and can be classified into 4 categories according to their pathophysiology: (1) specific, (2) reactive, (3) associated, and (4) induced by IBD treatment. Cutaneous manifestations are regarded as specific if they share with IBD the same granulomatous histopathological pattern: perianal or metastatic Crohn's disease (commonly presenting with abscesses, fistulas or hidradenitis suppurativa-like features) is the prototype of this setting. Reactive cutaneous manifestations are different from IBD in the histopathology but have close physiopathological links: pyoderma gangrenosum, a neutrophil-mediated autoinflammatory skin disease typically manifesting as painful ulcers, is the paradigm of this group. Among the cutaneous diseases associated with IBD, the most commonly seen are erythema nodosum, a form of panniculitis most commonly involving bilateral pretibial areas, and psoriasis, a T helper 1/T helper 17-mediated erythematous squamous inflammatory disease. Finally, the number of cutaneous adverse reactions because of IBD therapies is progressively increasing. The most frequent drug-induced cutaneous manifestations are psoriasis-like, eczema-like, and lichenoid eruptions, as well as cutaneous lupus erythematosus for biologics, and nonmelanoma skin cancer, mainly basal cell and squamous cell carcinomas for thiopurines.

show abstract

Section: Pyoderma Gangrenosummentioning

confidence: 99%

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

113

View full text Add to dashboard Cite

show abstract

“…34,35 Atypical and bullous types of PG are often associated with hematologic disorders and have been noted as a presenting sign of leukemia with some cases overlapping with Sweet syndrome. 32,[36][37][38][39][40][41][42] In a review of literature, around 35% of patients with postoperative PG had an associated systemic disease or a personal history of PG, with the majority of patients not having a predisposing comorbidity except surgery. 3,4 This is a greater systemic disease association compared with our cohort of 22% of postoperative PG cases; however, the lack of a standardized evaluation at our institution may be a confounding factor.…”

Section: Systemic Disease Associationsmentioning

confidence: 99%

Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014

Tolkachjov

Fahy

Wetter

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Since then, it has been reported that about 7% of all patients with PG have concurrent malignant neoplasms (3). This data is based largely on case reports, which have linked PG to pediatric acute lymphoblastic leukemia, adult and pediatric AML, and myelodysplastic syndromes (3)(4)(5)(6)(7)(8). In one recently reported case, a patient presented with PG and was not found to have AML until his cutaneous lesions were evaluated (5).…”

Section: Discussionmentioning

confidence: 95%

Pyoderma gangrenosum following tattoo placement in a patient with acute myelogenous leukemia

Jacobson

Martin

Deng

et al. 2008

Journal of Dermatological Treatment

View full text Add to dashboard Cite

A 37-year-old African American female with a diagnosis of acute myelogenous leukemia (AML) being treated with chemotherapy presented with a lesion on her lower back within the confines of a newly inked tattoo. Five days after tattoo placement, she developed an oozing, indurated, necrotic plaque at the site. Four days later, she developed chills, fever, and neutropenia. A skin biopsy was performed and was consistent with pyoderma gangrenosum (PG) or neutrophilic dermatoses. PG is an inflammatory skin disease associated with both cutaneous trauma and systemic disease, including hematologic malignancy. PG after tattoo placement, in both healthy patients and those with hematologic malignancies, has, to our knowledge, not yet been described in the literature. While further studies are necessary to investigate the link between PG and tattooing, oncologists may wish to counsel patients with leukemia to refrain from obtaining new tattoos.

show abstract

Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia

Cited by 39 publications

References 28 publications

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014

Pyoderma gangrenosum following tattoo placement in a patient with acute myelogenous leukemia

Contact Info

Product

Resources

About